eosera® vs Debrox: What the Published Evidence Actually Shows

You're standing in the aisle holding two boxes. Both promise to deal with earwax. One has been on the shelf for decades; the other is newer and cites laboratory studies you haven't had time to read. They don't work the same way, and the evidence behind each one is different in kind, not just degree.

This isn't a story about one product beating another. It's about two products with completely different underlying mechanisms that in turn lead to different timelines. Here's what that evidence actually says.

What Each Product Is

First, eosera® EAR WAX MD® is a patented dual-action bicarbonate and glycolic acid formulation designed to clean away earwax (U.S. Patent No. 10,596,106). It's labeled for ages 2 and up.1 It is widely distributed across all major retailers in the US and is at a premium price point in the category.

Debrox is an OTC drug marketed by Prestige Consumer Healthcare; it has been available to consumers for more than 50 years. Its active ingredient is 6.5% carbamide peroxide. Debrox is labeled for ages 12 and up, and its label reads to apply twice daily for up to four days. It's also widely distributed and sits at the lowest price point in the category.2 

Both are sold over-the-counter in the ear care section of the store. Neither requires a prescription. 

How Each One Works

Working through two mechanisms at once, eosera® EAR WAX MD®, leverages sodium bicarbonate to convert the wax esters and fatty acids in earwax into more water-soluble salts. At the same time, glycolic acid disrupts the calcium-dependent bonds that hold wax cells together.3 Together, the formulation is designed to break down cerumen structurally, rather than just soften it.

Debrox relies on carbamide peroxide, which releases oxygen on contact with earwax. That reaction is what produces the familiar fizzing sensation. Debrox works by softening and loosening wax gradually, over repeated applications across the recommended dosing period.

Neither mechanism is inherently better than the other. They're solving the same problem in different ways on different timelines.

What the Published Evidence Shows

In vitro study

A peer-reviewed in vitro study published in F1000Research compared the glycolic acid and bicarbonate formulation against two 6.5% carbamide peroxide products, testing all three on cerumen samples at 5, 10, 15, and 30 minutes. The glycolic acid and bicarbonate formulation produced substantial disintegration of the cerumen samples within 15 minutes, including 91% disintegration at five minutes versus 0% for the carbamide peroxide product in that comparison (p < 0.0001), across 86 human cerumen (earwax) samples. The 6.5% carbamide peroxide products tested showed minimal change to the cerumen samples at the same time points.3 

It's worth naming exactly what that means, and what it doesn't. This was a laboratory comparison of how the formulations act on cerumen (earwax) samples outside the body, not a head-to-head clinical trial comparing outcomes in patients. In vitro results describe chemical behavior under controlled conditions; they don't by themselves predict how any product performs across the range of human ears and real dosing habits. That gap is exactly why the clinical study below matters. The test-tube incubation and disintegration-grading approach itself follows methods used in earlier peer-reviewed in vitro cerumenolytic research.5,6,7

Clinical study 

A separate clinical study evaluated the sodium bicarbonate and glycolic acid formulation in adult patients with moderate to severe cerumen impaction. After a single application: 83% of ears (25 of 30) showed improvement, and 53% of ears (16 of 30) had wax totally dissolved, with full visibility of the tympanic membrane. After up to two applications, total dissolution reached 80% (24 of 30) on an intent-to-treat basis, and 86% (24 of 28) among patients who followed the irrigation instructions as directed.4 Participants also reported statistically significant improvements in blockage symptoms, including decreased hearing, tinnitus, feelings of fullness, and ear itching, and only one mild adverse event related to the application occurred (ear itching), which resolved without treatment. The trial is registered at ClinicalTrials.gov (NCT02829294).

Head-to-head laboratory study

In a head-to-head laboratory study, eosera® EAR WAX MD®, dissolved earwax faster than the leading carbamide-peroxide brand under laboratory conditions (p < 0.0001).3

Both the in vitro and clinical evidence are peer-reviewed and published. They also both list a co-founder of eosera® among the study authors. That affiliation doesn't invalidate the findings; peer review exists precisely to check the methodology independent of who funded or authored the study, but it is important to note. 

Practical Differences

Which Situation Suits Which

Debrox has a long track record, a low price, and the broadest shelf presence in the category.  It's a reasonable, well-established choice for someone who wants a familiar option and doesn't mind the standard multi-day dosing schedule.

eosera® EAR WAX MD®, may suit someone who wants a formulation backed by a published head-to-head laboratory comparison and human clinical data.

Neither is a substitute for the other's core strength: Debrox's decades of consumer use or the eosera® EAR WAX MD®, published comparative laboratory data and clinical results. 

When Neither Is the Answer

Earwax drops, of either kind, are designed for uncomplicated cerumen impaction, wax buildup without other symptoms. Neither product is the right first step if you have ear pain, drainage, bleeding, sudden hearing loss, dizziness, a known perforated eardrum, ear tubes, or a prior ear surgery. Those signs call for a clinician, not a drop. The American Academy of Otolaryngology–Head and Neck Surgery publishes a clinical practice guideline on when cerumen impaction needs professional care.8

FAQ

What is the main difference between eosera® EAR WAX MD® and Debrox?

Chemistry and timeline. Debrox uses carbamide peroxide to soften wax over repeated applications, while eosera® EAR WAX MD®, uses a dual-action bicarbonate and glycolic acid formula designed to dissolve it.

Has anyone tested them against each other?

Yes, in vitro. A published laboratory comparison found the glycolic acid and bicarbonate formulation disintegrated cerumen samples substantially within 15 minutes, while the carbamide peroxide products tested showed minimal change at the same interval. These were laboratory conditions on wax samples, not a patient trial.

Which one can I use for children?

Age labeling differs: eosera® EAR WAX MD®, is labeled for ages 2 and up, and Debrox is labeled for ages 12 and up. Check current product labeling before use.

Why does one fizz and the other does not?

Carbamide peroxide releases oxygen on contact, producing the fizzing sensation. The sodium bicarbonate and glycolic acid formula works through a different chemical mechanism and does not fizz. The fizzing does not mean that the product is working or not. 

The Bottom Line

Two mechanisms. Two timelines. Two price points. Two different bodies of evidence behind them. One is built on decades of consumer use, the other on published in vitro and clinical studies. The right question isn't which product wins. It's which mechanism, timeline, and evidence base fits your situation. 

Use as directed, and talk to a clinician if your symptoms go beyond ordinary wax buildup. 

You can learn more about eosera® EAR WAX MD®, here. 

References

1. Eosera. (n.d.). EAR WAX MD: Wax cleaning ear drops. Eosera. Retrieved August 12, 2026, from [https://www.eosera.com/products/eosera-ear-wax-md-wax-cleaning-ear-drops-earwax-removal-15ml#:~:text=This%20doctor%2Drecommended,wearers%2C%20and%20swimmers]

2. Prestige Consumer Healthcare. (n.d.). Debrox® Earwax Removal Aid Drops: Drug Facts. Retrieved August 12, 2026, from https://www.debrox.com

3. Knebl J, Harty B, Anderson CE, Dean WD, Griffin J. In vitro comparison of three earwax removal formulations for the disintegration of earwax. F1000Research. 2025;5:2784 (version 2). https://doi.org/10.12688/f1000research.10279.2

4. Fullington D, Song J, Gilles A, Guo X, Hua W, Anderson CE, Griffin J. Evaluation of the safety and efficacy of a novel product for the removal of impacted human cerumen. BMC Ear Nose Throat Disord. 2017;17:5. https://doi.org/10.1186/s12901-017-0038-8

5. Fraser JG. The efficacy of wax solvents: in vitro studies and a clinical trial. J Laryngol Otol. 1970;84(10):1055-1064.

6. Bellini MJ, Terry RM, Lewis FA. An evaluation of common cerumenolytic agents: an in-vitro study. Clin Otolaryngol Allied Sci. 1989;14(1):23-25.

7. Saxby C, Williams R, Hickey S. Finding the most effective cerumenolytic. J Laryngol Otol. 2013;127(11):1067-1070.

8. Schwartz SR, Magit AE, Rosenfeld RM, et al. Clinical practice guideline (update): earwax (cerumen impaction). Otolaryngol Head Neck Surg. 2017;156(1_suppl):S1-S29. https://doi.org/10.1177/0194599816671491